Earnings calls / TANFACIND · July 27, 2026

TANFAC Industries Limited Q1 FY27 Earnings Call Summary

Q1 FY27 revenue was ₹187 crores, up 6.3% YoY, but EBITDA margin fell to 15.3% and PAT dropped 13.4% to ₹16.8 crores. Solar-grade DHF ramp-up drove sales, while margins were hit by sulphur prices rising from ₹30 to ₹105/kg, higher power/fuel costs from the West Asia situation, and a sulfuric acid plant shutdown. Management guided FY27 revenue growth of ~30% and a 21-22% EBITDA margin, with HFC-32 commissioning in November 2026 and 65% of capacity contracted under take-or-pay. The main risk is sulphur price volatility with a 30-45 day cost pass-through lag; any HFC-32 commissioning delay could shift revenue contribution to FY28.

Revenue
Margin
Demand
Guidance
Tone

Event Participants

Executives

3 Afzal Malkani, Hemango Gupta, N.R. Ravichandran

Analysts

16 Aakash, Ankur Periwal, Dhruv Bajaj, Karan Kamdar, Meet Gada, Nirvana Laha, Preet Jain, Rajesh Gupta, Rikin Shah, Rohit Nagraj, Rudraksh Gupta, Samarth Goel, Sanjesh Jain, Shlok Patel, Siddharth Gadekar, Sujal Jhanwar

Financials & KPIs

Metric Reported Commentary
Revenue from Operations ₹187 crores +6.3% YoY (₹176 crores in Q1 FY26), -3% QoQ; driven by solar grade DHF ramp-up
Operating EBITDA ₹28.6 crores -1.4% YoY (₹29 crores in Q1 FY26); margin 15.3% vs 16.5% YoY
EBITDA Margin 15.3% -120 bps YoY; impacted by elevated sulphur prices (₹30→₹105/kg), higher power/fuel costs from West Asia situation, and sulfuric acid plant shutdown
Profit After Tax ₹16.8 crores -13.4% YoY (₹19.4 crores in Q1 FY26); impacted by lower EBITDA and deferred tax adjustment
AHF Realization ₹275-280/kg Stable for next 4-6 months; monthly/quarterly contracts, no long-term agreements
HF Plant Capacity Utilization 73% Down from prior periods; sulfuric acid plant at 85-88%, specialty fluorides at 50%
AHF Capacity ~30,000 MTPA Can produce 32,000-33,000 MTPA; 15,000 MTPA for captive R-32, 10,000 MTPA solar grade, 7,000-8,000 MTPA commercial sales
Solar Grade DHF Capacity 10,000 MTPA 80-85% contracted (3.5-year contracts); volume commitments with cost pass-through pricing
HFC-32 Project Capex ₹395 crores ₹315 crores committed, ₹100 crores cash outflow; on track for Q3 FY27 commissioning (Nov 2026)
HFC-32 Contracted Capacity 65% 5-7 year take-or-pay contracts; 75% exports, 25% domestic; $5.5/kg average pricing with cost pass-through
Net Debt Position Net debt-free Post ₹250 crores QIP and planned ₹100 crores preferential issue (₹61 crores from promoter Anupam Rasayan)
R&D Spend (Last 1.5 Years) ₹7-8 crores capex, ₹5-6 crores opex Team of 10+ professionals including 3-4 PhDs; 5-8 products in pipeline

Geographic & Segment Commentary

AHF (Anhydrous Hydrofluoric Acid): Domestic demand estimated at 30,000-35,000 MTPA. TANFAC operates ~30,000 MTPA capacity (73% utilization in Q1). One-third captive for solar grade DHF, ~4,000 MTPA for other captive use, balance sold to pharma/agro/refrigerant (one-third) and surface treatment/steel/glass/inorganic fluorides (one-third). Key customers: Jindal, Piramal, Cohizon, Tata, Adani, Premier Energies. No meaningful Chinese import threat due to dual-use chemical regulations and logistics constraints.

Solar Grade DHF: India's first and only domestic supplier. Both phases commissioned, running at full capacity with 80-85% contracted through FY29. Revenue contribution 35% of HF-based products. Pricing on cost pass-through basis. Immediate expansion planned (double capacity, ₹30-40 crores capex) as solar wafer capacity targets 210 GW by FY29 (from 35 GW currently), driving DHF demand from 30 KT to 210 KT.

HFC-32 (R-32 Refrigerant Gas): 20,000 MTPA project on schedule for November 2026 commissioning. 65% capacity contracted via 5-7 year take-or-pay agreements (two firm contracts, one MoU converting soon). 75% export-oriented. Project EBITDA margin targeted at ~30%. Expected revenue of ₹900-1,000 crores at full capacity. Will shift revenue mix from 90% domestic/10% export to 50/50.

Specialty Fluorides/Inorganic Fluorides: ~25% of HF-based revenue, 50% capacity utilization. Includes 4-5 products for pharma/agro applications. R&D pipeline includes 5-6 inorganic fluorides.

Company-Specific & Strategic Commentary

Capital Structure Transformation: Completed ₹250 crores QIP with strong institutional participation; board approved ₹100 crores preferential issue (₹61 crores from promoter Anupam Rasayan). Company now net debt-free with financial flexibility for expansion. NSE listing approval sought to improve liquidity and institutional participation.

Leadership Strengthening: Appointed Yogesh Mittal as President - Technical & Operations (30+ years experience in project execution, plant commissioning, manufacturing excellence) to support multiple strategic projects under execution.

Value Chain Integration: Expanded HF platform (30,000 MTPA) provides captive raw material security and foundation for downstream fluorochemicals. Solar grade DHF commercialized successfully. HFC-32 project execution on track with 65% pre-sold capacity.

Electronic Grade Chemicals: Evaluating technology tie-ups for semiconductor-grade DHF (100 PPT purity vs 10 PPB for solar grade = 1,000x purity jump). Approval cycle 1-1.5 years. Capex ~₹150 crores planned alongside AHF expansion (₹120 crores). Near-term priority after solar grade expansion.

Next-Generation Fluorochemicals: Targeting HFOs (low GWP gases) and high-performance fluoropolymers (niche/specialized, not commodity) for post-2028/29 launch. R&D halfway through technology development; patents expiring in ~3 years. Fluoropolymer products under customer approval (confidential). Total long-term capex pipeline ₹1,500-1,700 crores over 4 years.

Guidance & Outlook

Metric Guidance / Outlook Commentary
FY27 Revenue Growth ~30% YoY Driven by HFC-32 commissioning in Q4 and existing product ramp-up
FY28 Revenue Growth ~60% YoY (over FY27) Full-year HFC-32 contribution + solar grade expansion + inorganic fluorides
FY27 EBITDA Margin 21-22% (blended) Existing business 16-18%; Q4 HFC-32 contribution at higher margins lifts average
FY28 EBITDA Margin ~25% Full-year HFC-32 operation at ~30% project margins; structural margin improvement
HFC-32 Volume Utilization FY27 Q4: 65-70%; FY28: 80-85% (conservative), mgmt confident of 90%+ 65% contracted; balance spot. Vertical startup planned, stabilization by Feb 2027
AHF Capacity Expansion 20,000-30,000 MTPA by FY28 Commissioning FY28 (start FY27); supports HFOs, fluoropolymers, electronic grade
Solar Grade DHF Expansion ~Double capacity (₹30-40 crores) Immediate start post HFC-32 commissioning; driven by new solar player demand
Electronic Grade DHF Capex ~₹150 crores Tech tie-up evaluation underway; commercial revenues post 1-1.5 year approval cycle
HFOs/Fluoropolymers Execution post FY28, revenue by 2029-30 Capex part of ₹1,500-1,700 crores long-term plan; tech development underway

Risks & Constraints

Risk Context
Sulphur Price Volatility Price surged from ₹30 to ₹105/kg; 30-45 day cost pass-through lag creates quarterly margin volatility. Availability not an issue but pricing unpredictability persists.
Power & Fuel Cost Exposure Q1 impacted by West Asia geopolitical situation and sulfuric acid plant shutdown forcing grid power purchase. One-off in Q1 but structural exposure to energy costs remains.
HFC-32 Project Execution Commissioning targeted Nov 2026; machines arriving Sep 2026. Any delay in erection, catalyst loading, or stabilization could push revenue contribution to FY28.
Technology Risk - Electronic Grade 1,000x purity jump from solar grade (10 PPB → 100 PPT). Reliance on technology tie-ups to compress timeline; failure to absorb tech or secure partnerships could delay entry.
Customer Approval Cycles Semiconductor grade requires 1-1.5 year qualification with fabs. No revenue until approvals complete. Fluoropolymer approvals also underway but confidential.
AHF Demand Cannibalization HFC-32 will consume 15,000 MTPA captive HF, reducing commercial AHF sales by ~50% until new AHF capacity commissioned (FY28). Interim revenue gap.
Chinese Competition in AHF Currently limited by dual-use regulations, ISO tank logistics, and China's preference for downstream exports. Regulatory easing or logistics improvement could change dynamics.
Patent Landscape for Fluoropolymers/HFOs Management waiting for patent expirations (~3 years) for HFOs/fluoropolymers. Premature entry could face IP challenges; delayed entry risks missing market window.

Q&A Highlights

Revenue & Margin Outlook

  • Question: FY27/FY28 revenue outlook and margin trajectory with R-32 commissioning? (Meet Gada)
  • Answer: FY27: 30% revenue growth, 21-22% blended EBITDA margin. FY28: 60% growth, ~25% margin. HFC-32 project alone at ~30% EBITDA margin. (Afzal Malkani)

HFC-32 Contract Strategy

  • Question: 65% contracted at $5.5/kg vs spot at $9-10/kg - why not more spot exposure? (Dhruv Bajaj)
  • Answer: Speed-to-market priority as new entrant; forecast prices softening to $6-7 in 1-1.5 years. 65% locked at fixed EBITDA margin with cost pass-through; 35% spot for upside. (Hemango Gupta)

Solar Grade DHF Moat Durability

  • Question: Is first-mover advantage durable? Why no competitors? (Aakash)
  • Answer: Strict quality (≤10 PPB impurities), capex requirement, 4-5 month learning curve. Customer approvals take time. Currently approved at almost all solar customers. (Hemango Gupta)

Capex Pipeline & Phasing

  • Question: Near-term and long-term capex plans beyond HFC-32? (Sujal Jhanwar, Rohit Nagraj)
  • Answer: Near-term: Solar grade expansion (₹30-40 cr), AHF expansion

What you get with InvestorStack

Institutional-grade research, built for individual investors.

  • Research Reports for every listed Indian company
  • Detailed valuation models
  • Growth triggers, Risks, KPIs, Read between the lines
  • Scans, One pagers, Industry research reports
Try for free